COVID-19

Bharat Biotech’s Covid nasal vaccine gets regulator’s nod for holding phase 2, 3 trials

The first nasal COVID-19 vaccine developed by Bharat Biotech has got regulatory approval for phase second and third trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. The Department of Biotechnology said the phase one Clinical trial has been completed in the age groups ranging 18 to 60 years. The Company reports that the doses of the vaccine administered to healthy volunteers in this phase has been well tolerated and no serious adverse events have been reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The Department said the vaccine was able to elicit high level of neutralizing antibodies in animal studies.

Secretary, Department of Biotechnology, Dr. Renu Swarup, said that the Department through Mission COVID Suraksha is committed to development of safe and efficacious COVID-19 vaccines.

Click to comment

Leave a Reply

Your email address will not be published.

eight + 8 =

News is information about current events. News is provided through many different media: word of mouth, printing, postal systems, broadcasting, electronic communication, and also on the testimony of observers and witnesses to events. It is also used as a platform to manufacture opinion for the population.

Contact Info

Address:
D 601  Riddhi Sidhi CHSL
Unnant Nagar Road 2
Kamaraj Nagar, Goreagaon West
Mumbai 400062 .

Email Id: [email protected]

West Bengal

Eastern Regional Office
Indsamachar Digital Media
Siddha Gibson 1,
Gibson Lane, 1st floor, R. No. 114,
Kolkata – 700069.
West Bengal.

Office Address

251 B-Wing,First Floor,
Orchard Corporate Park, Royal Palms,
Arey Road, Goreagon East,
Mumbai – 400065.

Download Our Mobile App

IndSamachar Android App IndSamachar IOS App
To Top
WhatsApp WhatsApp us